» Articles » PMID: 12133721

Recent Advances in the Synthesis, Design and Selection of Cysteine Protease Inhibitors

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2002 Jul 23
PMID 12133721
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of cysteine proteases is emerging as an important strategy for the treatment of a variety of human diseases. Intense efforts involving structure-based inhibitor design have been directed toward several cysteine proteases, including cathepsin K, calpain, human rhinovirus 3C protease and several parasitic cysteine protease targets. Other successful recent efforts have involved combinatorial synthesis and screening for identification of new inhibitor templates.

Citing Articles

On the origins of SARS-CoV-2 main protease inhibitors.

Janin Y RSC Med Chem. 2024; 15(1):81-118.

PMID: 38283212 PMC: 10809347. DOI: 10.1039/d3md00493g.


Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.

Li L, Chenna B, Yang K, Cole T, Goodall Z, Giardini M J Med Chem. 2021; 64(15):11267-11287.

PMID: 34288674 PMC: 10504874. DOI: 10.1021/acs.jmedchem.1c00628.


SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells.

Cannalire R, Stefanelli I, Cerchia C, Beccari A, Pelliccia S, Summa V Int J Mol Sci. 2020; 21(16).

PMID: 32784899 PMC: 7460888. DOI: 10.3390/ijms21165707.


Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Siklos M, BenAissa M, Thatcher G Acta Pharm Sin B. 2015; 5(6):506-19.

PMID: 26713267 PMC: 4675809. DOI: 10.1016/j.apsb.2015.08.001.


The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.

Diefenbacher M, Popov N, Blake S, Schulein-Volk C, Nye E, Spencer-Dene B J Clin Invest. 2014; 124(8):3407-18.

PMID: 24960159 PMC: 4109555. DOI: 10.1172/JCI73733.